HIV-1 with I132M in RT decreases nucleotide selectivity

What is it about?

The HIV-1 reverse transcriptase mutation I132M, which confers high-level resistance to the nonnucleoside RT inhibitors (NNRTIs) nevirapine and delavirdine, is hypersusceptibility to the nucleoside analogs lamivudine (3TC) and tenofovir (TNV). The replication capacity of I132M HIV-1 is severely impaired, but could be partially or completely compensated by an additional RT mutation (A62V or L214I). These results probably accounts for the infrequent selection of I132M in patients who are failing NNRTI-containing therapy. Also, the single I132M mutation, which is outside of the polymerase active site and inside of the p51 subunit of RT, can significantly influence nucleotide selectivity.

Featured Image